UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 94

Sortiert nach

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Annals of oncology, 2019-08, Vol.30 (8), p.1289-1297

2019

Link zum Volltext

Verfügbarkeit prüfen

Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells

Oncogene, 2014-11, Vol.33 (47), p.5457-5466

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-09-20

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-08-19

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-06-39: Chest wall invasion is a more significant prognostic factor than nodal spread, triple-negative or Her2 receptor status in stage III breast cancer: A large, single institution retrospective analysis

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-39

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS1-10-GS1-10

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-03-06: LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/ HER2-negative, early-stage breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.OT1-03-06-OT1-03-06

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-06-06: RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate chemosensitivity in breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P4-P4-06-06

2012

Link zum Volltext

Verfügbarkeit prüfen

Partnership for problem solving is proposal of administration

Pennsylvania medicine, 1989-06, Vol.92 (6), p.30

Singel, M S

1989

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Link zum Volltext

Verfügbarkeit prüfen

Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry

Journal of allergy and clinical immunology, 2018-03, Vol.141 (3), p.1028-1035

2018

Link zum Volltext

Verfügbarkeit prüfen

Lawyering the 'Indian Child Welfare Act'

Michigan law review, 2022-06, Vol.120 (8), p.1755-1798

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Breast cancer research : BCR, 2018-09, Vol.20 (1), p.109-12, Article 109

2018

Link zum Volltext

Verfügbarkeit prüfen

Monocyte- and macrophage-targeted NADPH oxidase mediates antifungal host defense and regulation of acute inflammation in mice

The Journal of immunology (1950), 2013-04, Vol.190 (8), p.4175-4184

2013

Link zum Volltext

Verfügbarkeit prüfen

Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways

Breast cancer research : BCR, 2014-03, Vol.16 (2), p.R28-R28, Article R28

2014

Link zum Volltext

Verfügbarkeit prüfen

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The lancet oncology, 2017-10, Vol.18 (10), p.1360-1372

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study

Gynecologic oncology, 2017-09, Vol.146 (3), p.491-497

2017

Link zum Volltext

Verfügbarkeit prüfen

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Annals of oncology, 2016-11, Vol.27 (11), p.2059-2066

2016

Link zum Volltext

Verfügbarkeit prüfen

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

The lancet oncology, 2017-11, Vol.18 (11), p.e638-e638

2017

Link zum Volltext

Verfügbarkeit prüfen

KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer

Neoplasia (New York, N.Y.), 2014-03, Vol.16 (3), p.247-256.e2

2014

Link zum Volltext

Verfügbarkeit prüfen

Nitric oxide in the human respiratory cycle

Nature medicine, 2002-07, Vol.8 (7), p.711-717

2002

Link zum Volltext

Verfügbarkeit prüfen

Altering the Strength of Lectin Binding Interactions and Controlling the Amount of Lectin Clustering Using Mannose/Hydroxyl-Functionalized Dendrimers

Journal of the American Chemical Society, 2003-07, Vol.125 (29), p.8820-8826

2003

Link zum Volltext

Verfügbarkeit prüfen

Routes to S-Nitroso-Hemoglobin Formation with Heme Redox and Preferential Reactivity in the β Subunits

Proceedings of the National Academy of Sciences - PNAS, 2003-01, Vol.100 (2), p.461-466

2003

Link zum Volltext

Verfügbarkeit prüfen

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Journal for immunotherapy of cancer, 2022-07, Vol.10 (7), p.e004991

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(81)
Mit Volltextzugriff
(90)

Publikationsform

Sprache

Englisch
(93)
Japanisch
(13)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells

Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

Abstract P6-06-39: Chest wall invasion is a more significant prognostic factor than nodal spread, triple-negative or Her2 receptor status in stage III breast cancer: A large, single institution retrospective analysis

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Abstract OT1-03-06: LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/ HER2-negative, early-stage breast cancer

Abstract P4-06-06: RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate chemosensitivity in breast cancer

Partnership for problem solving is proposal of administration

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry

Lawyering the 'Indian Child Welfare Act'

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Monocyte- and macrophage-targeted NADPH oxidase mediates antifungal host defense and regulation of acute inflammation in mice

Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer

Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer

Nitric oxide in the human respiratory cycle

Altering the Strength of Lectin Binding Interactions and Controlling the Amount of Lectin Clustering Using Mannose/Hydroxyl-Functionalized Dendrimers

Routes to S-Nitroso-Hemoglobin Formation with Heme Redox and Preferential Reactivity in the β Subunits

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Suchergebnisse filtern